OneMedNet Significantly Expands Industry Access to Proprietary iRWD™ Network and Platform by Joining AWS Partner Network
June 06, 2024 07:40 ET
|
OneMedNet Corporation
MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of...
FirstService Expands Commercial Roofing Platform
June 06, 2024 07:30 ET
|
FirstService Corporation
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that its subsidiary, Roofing Corp of America (“RCA”), has acquired Crowther...
Research Frontiers and AIT Group Unveil Revolutionary Retrofittable SPD-SmartGlass Window At AIA Conference on Architecture & Design in Washington DC
June 06, 2024 07:30 ET
|
Research Frontiers Incorporated
Washington DC, June 06, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR), the inventor and licensor of patented SPD-Smart film light-control technology, and AIT Group, a...
Monster Beverage Corporation Announces Preliminary Results of Tender Offer
June 06, 2024 07:30 ET
|
Monster Beverage Corporation
CORONA, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (“Monster”) (NASDAQ: MNST) announced today the preliminary results of its modified “Dutch auction” tender offer, which...
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
June 06, 2024 07:30 ET
|
4D Molecular Therapeutics, Inc.
Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up ...
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
June 06, 2024 07:30 ET
|
Shattuck Labs, Inc.
- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck)...
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
June 06, 2024 07:30 ET
|
Venus Concept Inc.
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was...
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
June 06, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases...
Breckenridge Distillery Wins Double Gold for a Consecutive Year in a Row at the 2024 New York International Spirits Competition
June 06, 2024 07:30 ET
|
Tilray Brands, Inc.
Tilray's Breckenridge Distillery celebrated two major wins at this year's 15th annual New York International Spirits Competition.
Orion’s Q4’24 Revenue Rose 22% to $26.4M; FY’24 Revenue of $90.6M Driven by Growth Across LED Lighting, EV Charging and Maintenance Businesses; Targets FY 2025 Revenue Growth of 10-15%
June 06, 2024 07:29 ET
|
Orion Energy Systems, Inc.
Orion’s Q4’24 Revenue Rose 22% to $26.4M; FY’24 Revenue of $90.6M Driven by Growth Across LED Lighting, EV Charging and Maintenance Businesses.